Carobbio degli Angeli, Italy
Carobbio degli Angeli, Italy

Time filter

Source Type

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Alliance HealthCare Services, Inc. (NASDAQ: AIQ) (the “Company”, “Alliance”, “we” or “our”), a leading national provider of outsourced radiology, oncology and interventional services, announced today that Gregg Alan Dickerson, M.D., FACR, FACRO, has joined Alliance Cancer Centers in Greenville and Clarksdale and will be offering radiation oncology services to patients throughout Greenville, Clarksdale and the surrounding communities. “We are pleased to have Dr. Dickerson join the medical staff of the Alliance Cancer Centers in Greenville and Clarksdale,” said Candi Underwood, Site Administrator for the Alliance Cancer Centers in Greenville and Clarksdale. “Dr. Dickerson is a highly accomplished physician who brings over thirty years of radiation oncology experience to our cancer care treatment team and we are fortunate to have him care for the patients in our centers.” Gregg Alan Dickerson, M.D., FACR, FACRO, is a board certified radiation oncologist. Dr. Dickerson received his Bachelor of Arts with a double major in chemistry and biology from Indiana University in Bloomington, Indiana, and his medical degree from Indiana University School of Medicine in Indianapolis, Indiana. He completed his residency training in radiation oncology at the Bodine Center for Cancer Treatment at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania, where he also served as Chief Resident. In addition to his education and medical training, Dr. Dickerson spent 11 years serving our country as a flight surgeon in the Medical Corps of the Air National Guard, becoming a Major before being honorably discharged in 1996. Dr. Dickerson joined the Alliance Cancer Centers in Greenville and Clarksdale last October as an interim physician. “After many rewarding and productive years in Denver, Colorado, where I became highly specialized and accomplished for my work treating prostate cancer with radiosurgery, it was time to get ready for the next phase of my career,” said Dickerson. “It was at that time colleagues in the leadership of Alliance Oncology encouraged me to come to Mississippi to spend some time helping the good people of the Delta. What started off as a commitment for just a few months turned into a desire to continue caring for the dear people here and face the challenges that the spectrum of cancers they develop present. Joining the many other very compassionate physicians in the Delta and employing my advanced skills has been extremely satisfying and ultimately led to wanting to continue my work here.” Dr. Dickerson has been awarded over ten specialty honors and peer selected honors, including being ranked the number one radiation oncologist in Colorado in 2014 by HealthGrades.com. He also holds both military and civilian honors. He is a member of the American Society of Therapeutic Radiologists and Oncologists (ASTRO), the American College of Radiology (ACR), the American College of Radiation Oncology (ACRO), the Colorado Radiological Society, and the CyberKnife Society. For more information on Dr. Dickerson, or to schedule an appointment, please visit www.alliance-greenville-clarksdale.com. Alliance HealthCare Services (NASDAQ: AIQ) is a leading national provider of outsourced healthcare services to hospitals and providers. We also operate freestanding outpatient radiology, oncology and interventional services clinics, and Ambulatory Surgical Centers (“ASC”) that are not owned by hospitals or providers. Diagnostic radiology services are delivered through the Radiology Division (Alliance HealthCare Radiology), radiation oncology services are delivered through the Oncology Division (Alliance Oncology), and interventional and pain management services are delivered through the Interventional Division (Alliance Interventional). Alliance is the nation’s largest provider of advanced diagnostic mobile imaging services, an industry-leading operator of fixed-site imaging centers, and a leading provider of stereotactic radiosurgery nationwide. As of September 30, 2016, Alliance operated 619 diagnostic radiology and radiation therapy systems, including 112 fixed-site radiology centers across the country, and 32 radiation therapy centers and SRS facilities. With a strategy of partnering with hospitals, health systems and physician practices, Alliance provides quality clinical services for over 1,000 hospitals and other healthcare partners in 45 states, where approximately 2,400 Alliance Team Members are committed to providing exceptional patient care and exceeding customer expectations. For more information, visit www.alliancehealthcareservices-us.com.


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Alliance HealthCare Radiology (“Alliance Radiology”), a division of Alliance HealthCare Services, Inc. (NASDAQ:AIQ), announced today that it has established a partnership with Sodexo Healthcare, a $23B Euro global organization, serving clients for a comprehensive asset management solution for imaging equipment. “We are excited to partner with Sodexo, a company with broad market experience, strong financial performance, and a history of sustained growth over the last 50 years in the healthcare segment,” said Rich Jones, President of Alliance Radiology. “Our customers will benefit from this comprehensive program that goes well beyond the standard repair and maintenance program typically seen in our industry.” To meet the asset maintenance needs of Alliance Radiology’s over 1,000 hospital customers, Sodexo will begin with a subset of Alliance Radiology imaging assets, and expand the partnership over the next several years to maintain and service the majority of the company’s fleet of over 500 imaging equipment assets, through an Alliance dedicated call center and nationwide team of Imaging Service Engineers. “We are excited to partner with an industry leading organization like Alliance,” said Daniel Bueschel, CEO, Healthcare East, Sodexo North America. “Sodexo’s Clinical Technology Management solution has a proven track record of driving efficiency, mitigating risk of equipment failure and reducing costs. We look forward to helping Alliance Radiology continue to deliver an exceptional level of service and care to their clients and patients.” “We are partnering with Sodexo to create a fully integrated asset management lifecycle solution beyond the basic offering currently provided by the market,” explained Dale Hockel, Chief Operations Officer at Alliance Radiology. “This includes the total management of assets—from initial customer planning through end of life, with a strong focus on preventive maintenance. Maximizing asset uptime and extending the life of our assets brings value to our customers while delivering a remarkable experience to our shared patients.” With over 30 years of industry experience, Alliance Radiology is the partner of choice for hundreds of hospitals and healthcare practices across the United States. Alliance Radiology is known for their patient care and satisfaction having earned Avatar International’s “Exceeding Patient Expectations” award every year since 2007. Sodexo delivers more than 100 services across North America that enhance organizational performance, contribute to local communities and improve quality of life. The Fortune Global 500 company is a leader in delivering sustainable, integrated facilities management and foodservice operations. Sodexo Healthcare provides quality of life services in 4,300 hospitals, across 34 countries, utilizing the depth and breadth of experience from more than 60,000 Sodexo Healthcare professionals. Our vast array of solutions address key healthcare issues including the patient experience in the US, equitable access in the UK, community services in Brazil and the Netherlands, and clinical technology management solutions in Thailand, among others. Alliance HealthCare Services (NASDAQ: AIQ) is a leading national provider of outsourced healthcare services to hospitals and providers. We also operate freestanding outpatient radiology, oncology and interventional services clinics, and Ambulatory Surgical Centers (“ASC”) that are not owned by hospitals or providers. Diagnostic radiology services are delivered through the Radiology Division (Alliance HealthCare Radiology), radiation oncology services are delivered through the Oncology Division (Alliance Oncology), and interventional and pain management services are delivered through the Interventional Division (Alliance Interventional). Alliance is the nation’s largest provider of advanced diagnostic mobile imaging services, an industry-leading operator of fixed-site imaging centers, and a leading provider of stereotactic radiosurgery nationwide. As of September 30, 2016, Alliance operated 619 diagnostic radiology and radiation therapy systems, including 112 fixed-site radiology centers across the country, and 32 radiation therapy centers and SRS facilities. With a strategy of partnering with hospitals, health systems and physician practices, Alliance provides quality clinical services for over 1,000 hospitals and other healthcare partners in 45 states, where approximately 2,400 Alliance Team Members are committed to providing exceptional patient care and exceeding customer expectations. For more information, visit www.alliancehealthcareservices-us.com.


News Article | October 28, 2016
Site: www.marketwired.com

LA JOLLA, CA--(Marketwired - Oct 24, 2016) - Panther Biotechnology, Inc. ( : PBYA) today announced that a Pre-Investigational New Drug (Pre-IND) meeting with the Divison of Oncology Products 1 (DOP1) of the Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA) has been granted by FDA. The meeting with the Oncology Division of FDA will take the form of written responses to Panther's Pre-IND package and questions regarding the development of TRF-DOX, Panther's novel transferrin-doxorubicin conjugate for the treatment of platinum-resistant ovarian cancer. In preparation for FDA's feedback, Panther is preparing a Pre-IND Package to be submitted to FDA that describes the information Panther intends on submitting in the TRF-DOX IND planned for submission in 2017. The IND is the regulatory vehicle that will permit the initiation of clinical trials with TRF-DOX in the U.S. FDA will specifically review Panther's manufacturing, preclinical pharmacology and toxicology, and clinical plans for TRF-DOX and provide specific feedback to Panther by the end of the year. TRF-DOX binds to transferrin receptors on tumor cells, inhibits cancer cell proliferation and causes cell death. TRF-DOX has been shown to exhibit increased cytotoxicity relative to unconjugated doxorubicin toward a variety of cancer cell lines and reduced cytotoxicity to normal cells. In addition to improvements in cytotoxicity and selectivity, TRF-DOX exhibits cytotoxic effects in many multidrug-resistant cells in vitro. Tumor targeting of doxorubicin to transferrin receptors on the cell membranes of tumor cells is intended to improve the therapeutic index of doxorubicin and to reduce the development of doxorubicin resistance. Panther is proposing to conduct an open label Phase 2a, multiple ascending dose study to investigate the safety, pharmacokinetics and preliminary efficacy of TRF-DOX in patients with platinum-resistant ovarian cancer. Panther Biotechnology, Inc. has been an entity focused on the acquisition and development of enhanced therapeutics for the treatment of neoplastic, autoimmune and antiviral disorders. The Company has recently announced a letter of intent to acquire Brown Technical Media Corp. to diversify its business interests and adjust its investment risk profile.


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Alliance HealthCare Services (NASDAQ:AIQ) announced today that it will host a conference call and webcast on Thursday, March 9, 2017, at 5 p.m. Eastern Time, to discuss the Company’s fourth quarter and full year 2016 financial results, which are scheduled to be released after the market closes on Thursday, March 9, 2017. Tom Tomlinson, Chief Executive Officer and President, is scheduled to host the call. Also scheduled to participate is Rhonda Longmore-Grund, Chief Financial Officer and Executive Vice President. The conference call can be accessed at 877-638-4550 (International callers can dial 443-961-0596). Interested parties should call at least five minutes prior to the call to register. A telephone replay will be available until May 3, 2017. The telephone replay can be accessed by calling 800-585-8367. The conference call identification number is 10068564. Additionally, a live webcast of the call will be available on the Company’s website at www.alliancehealthcareservices-us.com. Click on “About Us,” then, “Investor Relations.” You will find the Audio Presentation in the “News & Events” section. A replay of the webcast will be available on the Company’s website until May 9, 2017. Alliance HealthCare Services (NASDAQ: AIQ) is a leading national provider of outsourced healthcare services to hospitals and providers. We also operate freestanding outpatient radiology, oncology and interventional services clinics, and Ambulatory Surgical Centers (“ASC”) that are not owned by hospitals or providers. Diagnostic radiology services are delivered through the Radiology Division (Alliance HealthCare Radiology), radiation oncology services are delivered through the Oncology Division (Alliance Oncology), and interventional and pain management services are delivered through the Interventional Division (Alliance Interventional). Alliance is the nation’s largest provider of advanced diagnostic mobile imaging services, an industry-leading operator of fixed-site imaging centers, and a leading provider of stereotactic radiosurgery nationwide. As of September 30, 2016, Alliance operated 619 diagnostic radiology and radiation therapy systems, including 112 fixed-site radiology centers across the country, and 32 radiation therapy centers and SRS facilities. With a strategy of partnering with hospitals, health systems and physician practices, Alliance provides quality clinical services for over 1,000 hospitals and other healthcare partners in 45 states, where approximately 2,400 Alliance Team Members are committed to providing exceptional patient care and exceeding customer expectations. For more information, visit www.alliancehealthcareservices-us.com.


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Alliance HealthCare Services, Inc. (NASDAQ: AIQ) (the “Company”, “Alliance”, “we” or “our”), a leading national provider of outsourced radiology, oncology and interventional services, announced today that it has received a letter (the “Expression of Interest”) describing a non-binding proposal from Tahoe Investment Group Co., Ltd. (“Tahoe”), formerly known as Fujian Thai Hot Investment Co., Ltd, to acquire all of the outstanding common shares of Alliance that are not currently owned by THAIHOT Investment Company Limited (“THAIHOT”), an indirect wholly owned subsidiary of Tahoe. Tahoe has proposed a purchase price of $9.60 per share in cash. As previously disclosed on March 29, 2016, Tahoe, through its subsidiary, completed the purchase of the majority interest in Alliance, owning an aggregate of approximately 52% of outstanding common stock, and entered into a Governance, Voting and Standstill Agreement (the “Governance Agreement”) with the Company. The Board of Directors of the Company has authorized a Special Committee, comprised solely of directors not affiliated with Tahoe, to evaluate the Expression of Interest. The Special Committee has engaged independent legal counsel and intends to engage an independent financial advisor to assist in its evaluation of the Expression of Interest. In connection with the Expression of Interest, the Special Committee has agreed to waive the provision of the Governance Agreement prohibiting THAIHOT and its affiliates, including Tahoe, from proposing to acquire additional shares of the Company’s common stock. The waiver is for the limited purpose of submitting the Expression of Interest to the Special Committee. The Expression of Interest indicated that any transaction with Tahoe would be subject to approval by the Special Committee and a non-waiveable condition requiring approval of a majority of the shares of Alliance not owned by Tahoe or is affiliates. Tahoe also indicated that the proposed transaction would not be subject to a financing condition. About Alliance HealthCare Services Alliance HealthCare Services (NASDAQ: AIQ) is a leading national provider of outsourced healthcare services to hospitals and providers. We also operate freestanding outpatient radiology, oncology and interventional services clinics, and Ambulatory Surgical Centers (“ASC”) that are not owned by hospitals or providers. Diagnostic radiology services are delivered through the Radiology Division (Alliance HealthCare Radiology), radiation oncology services are delivered through the Oncology Division (Alliance Oncology), and interventional and pain management services are delivered through the Interventional Division (Alliance Interventional). Alliance is the nation’s largest provider of advanced diagnostic mobile imaging services, an industry-leading operator of fixed-site imaging centers, and a leading provider of stereotactic radiosurgery nationwide. As of September 30, 2016, Alliance operated 619 diagnostic radiology and radiation therapy systems, including 112 fixed-site radiology centers across the country, and 32 radiation therapy centers and SRS facilities. With a strategy of partnering with hospitals, health systems and physician practices, Alliance provides quality clinical services for over 1,000 hospitals and other healthcare partners in 45 states, where approximately 2,400 Alliance Team Members are committed to providing exceptional patient care and exceeding customer expectations. For more information, visit www.alliancehealthcareservices-us.com. About Tahoe Tahoe is an investment holding company based in Fuzhou, China, holding a diversified portfolio of assets in various industries including real estate development, securities, hospitality, biomedicine and healthcare. Tahoe was founded in 1996 and its total assets exceeded $13 billion as of December 31, 2015. Tahoe’s diversified portfolio includes controlling ownership in Thai Hot Group, one of the leading real-estate developers in China listed on the Shenzhen Stock Exchange (SZSE:000732). Tahoe is also the third largest shareholder of the Shanghai Stock Exchange listed Dongxing Securities (SHSE:601198). Tahoe expanded its business landscape to include biomedicine and healthcare industry by acquiring a large-scale pharmaceutical company. In early 2015, Tahoe made healthcare and medical services one of its top priorities, including radiology and oncology, and it intends to expand healthcare services in mainland China to an underserved healthcare marketplace. Qisen Huang is the Founder and Chairman of Tahoe. Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, without limitation, the Company’s long-term value proposition, growth and international market and other opportunities. Forward-looking statements can be identified by the use of forward looking language such as “believe,” “anticipate,” “expect,” “estimate,” “intend,” “plan,” “project,” “will be,” “will continue,” “will result,” “could,” “may,” “might,” or any variations of such words with similar meanings. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. These statements involve risks and uncertainties that could cause actual results to differ materially from those projected. For a complete list of risks and uncertainties, please refer to the Risk Factors section of the Company’s Form 10-K for the year ended December 31, 2015 filed with the Securities and Exchange Commission.


News Article | February 16, 2017
Site: www.accesswire.com

TORONTO, ON / ACCESSWIRE / February 16, 2017 / Wi2Wi Corporation (Wi2Wi or the Company) (TSX-V: YTY), announces that Mr. Daniel Phelan has resigned as a director and Chairman of the Board of Directors. Mr. Michael R. Sonnenreich and Fraser C. Henderson Sr., M.D have joined the Board of Directors and Mr. Sonnenreich was elected as the Chairman of the Board of Directors. Mr. Sonnenreich is a lawyer and a philanthropist and has extensive management experiences in various industries; Technology, Pharmaceutical and Global Marketing. He is an active stake holder and advisor to several national and international companies. Currently, Mr. Sonnenreich is the Chairman of the Board of Kikaku America International, and Vice Chairman of PharMa International Corporation of Tokyo, Japan. He is a graduate of the University of Wisconsin, the University of Madrid, Spain, and Harvard University Law School. In the past twelve years Mr. Sonnenreich has served as a board member and trustee of numerous important companies and universities, including Williams Creek Explorations, Vancouver, British Columbia, Canada; Wi2Wi, San Jose, California; Tyhee Development Corp. Ltd., Vancouver, British Columbia, Canada; Les Aliments SoYummi, Inc., Montreal, Canada; the ABD American Capital Market Funds; the Integra Fund; Continental Steel Inc.; Amorfix Life Sciences Ltd. (now Promis Neurosciences), Vancouver, British Columbia, Canada; Scientific American; and Medical Tribune International. Mr. Sonnenreich has had long-term involvement with many nonprofit institutions. These include the Washington National Opera (President 1996-98; 2002-2006); D.C. Jazz Festival (Chairman, 2010-2014); Sackler/Freer Galleries of Art (Smithsonian Institution), D.C.; Commission on the Arts and Humanities (Mayoral Appointment as Commissioner, 2008-2011); the Johns Hopkins University School of Advanced International Studies; the New England Conservatory of Music; the North Carolina Museum of Art Foundation; the University of Virginia Art Museum; Clark University; the Maret School; and the Richard Tucker Music Foundation. Mr. Sonnenreich served as President of the National Coordinating Council on Drug Education. In 2008, he was named Distinguished Washingtonian by the University Club of Washington, D.C. He previously served in government in the Department of Justice and was appointed Executive Director of the National Commission on Marijuana and Drug Abuse. Dr. Henderson is a world renowned Board-certified Neurological Surgeon and a retired US Navy Commander. He has received both his bachelor's and Medical degree from the University of Virginia, Charlottesville Virginia. He completed his fellowship in Craniospinal surgery under Professor Alan Crockard at The National Hospital for Neurology and Neurosurgery, Queen Square, London. As Part of his active duty obligations; Dr. Henderson was the Director of Spine at National Naval Medical Center, Bethesda, MD and was Brigade Neurosurgeon for the 4th Marine Expeditionary Brigade in Desert Shield and Desert Storm during the 1st Gulf War. Finishing his tour with the US Navy, Commander Henderson joined Georgetown University, in Washington D.C. as Director of Neurosurgery of the Spine and Cranio-cervical Junction. He was Co-Director of the Lombardi Neuro-Oncology Division, Co-Director of the CyberKnife Radiosurgery Center, and Medical Director of the Neuroscience Nursing Units. He was Professor of Neurosurgery and Radiology at Georgetown University, where he was active in advancing CyberKnife radiosurgery for treatment of chordoma and other complex spinal tumors. He is the Director of Neurosurgery at Doctors Hospital and Director of the Chiari Center of Excellence, where he is focused on the development of the understanding and treatment of deformity induced injury to the brainstem and spinal cord in Chiari Malformation and Ehlers Danlos Syndrome. Dr. Henderson developed intellectual property for three inventions relating to spinal radiosurgery and spinal cancer, including the TPS® -Telescopic Plate Spacer- a vertebral replacement device for metastatic disease and was Principal Investigator in the translational development of a radio-sensitizing drug, and a drug to block the malignant invasiveness of Glioblastoma Multiforme. He is an inventor of 11 devices and concepts relating to disorders of the brainstem and spinal cord, and has published over 50 peer reviewed articles and book chapters, and given over 120 invited lectures with a focus on craniocervical disorders, Chiari malformation, cancer, radiosurgery and unusual problems of the spine "We are excited to have both Mr. Sonnenreich and Mr. Henderson in the Board. Their vast experience and expertise will definitely guide the company into the successful future," said Zachariah Mathews, President and CEO of Wi2Wi. "The Board expresses its profound appreciation to Mr. Daniel Phelan for the business and financial expertise he brought to the board of directors over the past three years and helping the management of the company," said the Chairman of the Board Mr. Michael Sonnenreich. For further information, please contact: Essentially, IoT and M2M describe the network of physical objects or "things" embedded with electronics, software, sensors, and network connectivity, which enables these objects to collect and exchange data. Driven by several factors including the growth in the availability of Broadband Internet, which reduces the cost of connecting, and the related increase in Wi-Fi capabilities as well as sensors built into myriad technologies, this has been described as the "perfect storm" for the IoT. Almost any device with an on and off switch that can be connected to the Internet (and/or to each other) - anything from cell phones, coffee makers, washing machines, headphones, lamps, wearable devices, cars, as well as machine components in the engine of a jet airplane or the drill of an oil rig. According to analyst firm Gartner, by 2020 there will be over 26 billion connected devices. Others think this figure could be too conservative by a factor of four. Wi2Wi is a vertically-integrated technology company which designs, manufactures and markets high performance, low power wireless connectivity solutions, global navigation satellite system (GNSS) modules, and frequency control devices. The Company's products and services address numerous applications in the markets of Internet of Things (IoT), Machine to Machine (M2M), Avionics, Space, and Government Sponsored Projects. Wi2Wi's products and value-added services provide highly integrated, rugged, robust, and reliable multiprotocol wireless actuators with embedded software, along with customized timing and frequency control devices for customers, worldwide. The Company was founded in 2005 and is strategically headquartered in San Jose, California with satellite offices in Middleton, Wisconsin and Hyderabad, India. Wi2Wi's manufacturing operations, its laboratory for reliability and quality control, together with design and engineering for timing and frequency control devices are located in Middleton, WI. The branch office, located in Hyderabad, India, focuses on the development of wireless connectivity; both hardware and software. Wi2Wi's strategic objective is to service the unique needs of each customer by providing end to end wireless integration solutions and highly customizable timing and frequency control devices. Wi2Wi distinguishes itself from commodity grade products, with best in the market performance, highly reliable, low power wireless connectivity products with integrated software that supports broader temperature ranges and a longer product life cycle. Furthermore, Wi2Wi's end to end product solutions helps the customer substantially reduce their end product expense, certification cost, and overall R&D investment, in addition to substantially reducing the time to market. Wi2Wi has partnered with best in class global leaders in technology, manufacturing, and sales. The Company uses a wide network of manufacturer's representatives, worldwide, to promote its products and services, and has partnered with world class distributors for the fulfillment of orders along with direct sales. Forward-Looking Statements: This news release contains certain forward-looking statements, including management's assessment of future plans and operations, and the timing thereof, that involve substantial known and unknown risks and uncertainties, certain of which are beyond the Company's control. Such risks and uncertainties include, without limitation, risks associated with the ability to access sufficient capital, the impact of general economic conditions in Canada, the United States and overseas, industry conditions, stock market volatility. The Company's actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what benefits, including the amount of proceeds, that the Company will derive there from. Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information on these and other factors that could affect the Company's operations and financial results are included in reports on file with Canadian securities regulatory authorities and may be accessed through the SEDAR website (www.sedar.com). Forward-looking statements are made based on management's beliefs, estimates and opinions on the date the statements are made and the Company undertakes no obligation to update forward-looking statements and if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law. All subsequent forward-looking statements, whether written or oral, attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Furthermore, the forward-looking statements contained in this news release are made as at the date of this news release and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced two high-level appointments designed to further strengthen the company’s public affairs and business development capabilities following the launch of its newest medicine, CABOMETYX™, earlier this year. Susan Hubbard has joined the company as Executive Vice President of Public Affairs and Investor Relations, and Stefan Krauss, Ph.D. has joined as Vice President of Business Development. “The regulatory approval and launch of CABOMETYX earlier this year has provided a strong foundation for the next phase of Exelixis’ growth,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer at Exelixis. “In welcoming Susan and Stefan to Exelixis, we are positioning the company for a transformational period, and we are confident that their unique expertise will strengthen our ability to advance the company as it continues to evolve.” As EVP of Public Affairs and Investor Relations, Susan Hubbard will oversee the company’s public affairs, advocacy and investor relations functions as a member of the company’s executive leadership team. Prior to joining Exelixis in a full-time capacity, Ms. Hubbard served as an independent public affairs and investor relations consultant to the biopharmaceutical industry. From 2014 onward, she was instrumental in developing Exelixis’ communications strategy around the late-stage clinical development, approval and commercial launch of CABOMETYX, as well as several major milestones for the company’s partnered programs. Previously, as one of the initial employees at Gilead Sciences she spent over two decades in roles of increasing responsibility, finishing her tenure as Vice President of Investor Relations. She received her undergraduate degree from University of California, Los Angeles. As Vice President of Business Development, Stefan Krauss, Ph.D. will lead Exelixis’ business development activities and its ongoing partnering and in-licensing initiatives as the company seeks to expand its pipeline of oncology therapeutics. Before joining Exelixis, from 2014 to 2016 Dr. Krauss served as a Senior Director of Business Development and Licensing at Baxalta (formerly Baxter Bioscience). At Baxalta, he led oncology business development for the company’s newly-formed Oncology Division and was instrumental in adding transformational and innovative partnerships to the company’s rapidly growing oncology portfolio. Prior to that, from 2011 to 2014 Dr. Krauss served as Director of Search and Evaluation Oncology in the Global Business Development unit of EMD Serono, where he identified and evaluated strategic oncology and immuno-oncology in-licensing opportunities for the company. Previously, Dr. Krauss held positions of increasing responsibility at Merck Research Laboratories as a senior scientist and team leader as well as in scientific business development, most recently as a Senior Manager and Research Fellow, Global External Basic Research (Oncology). Before entering the pharmaceutical industry, Dr. Krauss was a Research Fellow in Medicine at Beth Israel Deaconess Medical Center and Harvard Medical School. He holds both M.Phil. and Ph.D. degrees in biochemistry from the University of Cambridge (UK). The new appointments underscore the company’s growth trajectory and will further Exelixis’ efforts in addressing increased interest from media, investors and potential partners. Exelixis, Inc. (Nasdaq: EXEL) is a biopharmaceutical company committed to the discovery, development and commercialization of new medicines with the potential to improve care and outcomes for people with cancer. Since its founding in 1994, three medicines discovered at Exelixis have progressed through clinical development to receive regulatory approval. Currently, Exelixis is focused on advancing cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL and VEGF receptors, which has shown clinical anti-tumor activity in more than 20 forms of cancer and is the subject of a broad clinical development program. Two separate formulations of cabozantinib have received regulatory approval to treat certain forms of kidney and thyroid cancer and are marketed for those purposes as CABOMETYX™ tablets (U.S. and EU) and COMETRIQ® capsules (U.S. and EU), respectively. Another Exelixis-discovered compound, COTELLIC® (cobimetinib), a selective inhibitor of MEK, has been approved in major territories including the United States and European Union, and is being evaluated for further potential indications by Roche and Genentech (a member of the Roche Group) under a collaboration with Exelixis. For more information on Exelixis, please visit www.exelixis.com or follow @ExelixisInc on Twitter. This press release contains forward-looking statements, including, without limitation, statements related to: the impact of the two high-level appointments on the strength of Exelixis’ public affairs and business development capabilities, and the ability to advance the company as it continues to evolve; the next phase of Exelixis’ growth; Exelixis’ plans to seek to expand its pipeline of oncology therapeutics; Exelixis’ growth trajectory; Exelixis' commitment to the discovery, development and commercialization of new medicines with the potential to improve care and outcomes for people with cancer; Exelixis’ focus on advancing cabozantinib; and the continued development of cobimetinib. Words such as “further,” “next,” “will,” “continue,” “committed,” “focused,” “potential,” or other similar expressions identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements are based upon Exelixis’ current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: Exelixis’ ability to successfully address increasing interest from media, investors and potential partners; Exelixis’ ability to enter into future collaborations on acceptable terms; the risk that unanticipated developments could adversely affect the commercialization of CABOMETYX or COMETRIQ; Exelixis’ ability to conduct clinical trials of cabozantinib sufficient to achieve a positive completion and risks related to the potential failure of cabozantinib to demonstrate safety and efficacy in clinical testing; Exelixis’ dependence on its relationship with Ipsen, including, the level of Ipsen’s investment in the resources necessary to successfully commercialize cabozantinib in the territories where it is approved; Exelixis’ dependence on its relationship with Genentech/Roche with respect to cobimetinib and Exelixis’ ability to maintain its rights under the collaboration; Exelixis’ dependence on third-party vendors; Exelixis’ ability to protect the company’s intellectual property rights; market competition; changes in economic and business conditions, and other factors discussed under the caption “Risk Factors” in Exelixis’ quarterly report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 3, 2016, and in Exelixis’ future filings with the SEC. The forward-looking statements made in this press release speak only as of the date of this press release. Exelixis expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Exelixis’ expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Exelixis, the Exelixis logo, COMETRIQ and COTELLIC are registered U.S. trademarks, and CABOMETYX is a U.S. trademark.


News Article | February 16, 2017
Site: marketersmedia.com

TORONTO, ON / ACCESSWIRE / February 16, 2017 / Wi2Wi Corporation (Wi2Wi or the Company) (TSX-V: YTY), announces that Mr. Daniel Phelan has resigned as a director and Chairman of the Board of Directors. Mr. Michael R. Sonnenreich and Fraser C. Henderson Sr., M.D have joined the Board of Directors and Mr. Sonnenreich was elected as the Chairman of the Board of Directors. Mr. Sonnenreich is a lawyer and a philanthropist and has extensive management experiences in various industries; Technology, Pharmaceutical and Global Marketing. He is an active stake holder and advisor to several national and international companies. Currently, Mr. Sonnenreich is the Chairman of the Board of Kikaku America International, and Vice Chairman of PharMa International Corporation of Tokyo, Japan. He is a graduate of the University of Wisconsin, the University of Madrid, Spain, and Harvard University Law School. In the past twelve years Mr. Sonnenreich has served as a board member and trustee of numerous important companies and universities, including Williams Creek Explorations, Vancouver, British Columbia, Canada; Wi2Wi, San Jose, California; Tyhee Development Corp. Ltd., Vancouver, British Columbia, Canada; Les Aliments SoYummi, Inc., Montreal, Canada; the ABD American Capital Market Funds; the Integra Fund; Continental Steel Inc.; Amorfix Life Sciences Ltd. (now Promis Neurosciences), Vancouver, British Columbia, Canada; Scientific American; and Medical Tribune International. Mr. Sonnenreich has had long-term involvement with many nonprofit institutions. These include the Washington National Opera (President 1996-98; 2002-2006); D.C. Jazz Festival (Chairman, 2010-2014); Sackler/Freer Galleries of Art (Smithsonian Institution), D.C.; Commission on the Arts and Humanities (Mayoral Appointment as Commissioner, 2008-2011); the Johns Hopkins University School of Advanced International Studies; the New England Conservatory of Music; the North Carolina Museum of Art Foundation; the University of Virginia Art Museum; Clark University; the Maret School; and the Richard Tucker Music Foundation. Mr. Sonnenreich served as President of the National Coordinating Council on Drug Education. In 2008, he was named Distinguished Washingtonian by the University Club of Washington, D.C. He previously served in government in the Department of Justice and was appointed Executive Director of the National Commission on Marijuana and Drug Abuse. Dr. Henderson is a world renowned Board-certified Neurological Surgeon and a retired US Navy Commander. He has received both his bachelor's and Medical degree from the University of Virginia, Charlottesville Virginia. He completed his fellowship in Craniospinal surgery under Professor Alan Crockard at The National Hospital for Neurology and Neurosurgery, Queen Square, London. As Part of his active duty obligations; Dr. Henderson was the Director of Spine at National Naval Medical Center, Bethesda, MD and was Brigade Neurosurgeon for the 4th Marine Expeditionary Brigade in Desert Shield and Desert Storm during the 1st Gulf War. Finishing his tour with the US Navy, Commander Henderson joined Georgetown University, in Washington D.C. as Director of Neurosurgery of the Spine and Cranio-cervical Junction. He was Co-Director of the Lombardi Neuro-Oncology Division, Co-Director of the CyberKnife Radiosurgery Center, and Medical Director of the Neuroscience Nursing Units. He was Professor of Neurosurgery and Radiology at Georgetown University, where he was active in advancing CyberKnife radiosurgery for treatment of chordoma and other complex spinal tumors. He is the Director of Neurosurgery at Doctors Hospital and Director of the Chiari Center of Excellence, where he is focused on the development of the understanding and treatment of deformity induced injury to the brainstem and spinal cord in Chiari Malformation and Ehlers Danlos Syndrome. Dr. Henderson developed intellectual property for three inventions relating to spinal radiosurgery and spinal cancer, including the TPS® -Telescopic Plate Spacer- a vertebral replacement device for metastatic disease and was Principal Investigator in the translational development of a radio-sensitizing drug, and a drug to block the malignant invasiveness of Glioblastoma Multiforme. He is an inventor of 11 devices and concepts relating to disorders of the brainstem and spinal cord, and has published over 50 peer reviewed articles and book chapters, and given over 120 invited lectures with a focus on craniocervical disorders, Chiari malformation, cancer, radiosurgery and unusual problems of the spine "We are excited to have both Mr. Sonnenreich and Mr. Henderson in the Board. Their vast experience and expertise will definitely guide the company into the successful future," said Zachariah Mathews, President and CEO of Wi2Wi. "The Board expresses its profound appreciation to Mr. Daniel Phelan for the business and financial expertise he brought to the board of directors over the past three years and helping the management of the company," said the Chairman of the Board Mr. Michael Sonnenreich. For further information, please contact: Essentially, IoT and M2M describe the network of physical objects or "things" embedded with electronics, software, sensors, and network connectivity, which enables these objects to collect and exchange data. Driven by several factors including the growth in the availability of Broadband Internet, which reduces the cost of connecting, and the related increase in Wi-Fi capabilities as well as sensors built into myriad technologies, this has been described as the "perfect storm" for the IoT. Almost any device with an on and off switch that can be connected to the Internet (and/or to each other) - anything from cell phones, coffee makers, washing machines, headphones, lamps, wearable devices, cars, as well as machine components in the engine of a jet airplane or the drill of an oil rig. According to analyst firm Gartner, by 2020 there will be over 26 billion connected devices. Others think this figure could be too conservative by a factor of four. Wi2Wi is a vertically-integrated technology company which designs, manufactures and markets high performance, low power wireless connectivity solutions, global navigation satellite system (GNSS) modules, and frequency control devices. The Company's products and services address numerous applications in the markets of Internet of Things (IoT), Machine to Machine (M2M), Avionics, Space, and Government Sponsored Projects. Wi2Wi's products and value-added services provide highly integrated, rugged, robust, and reliable multiprotocol wireless actuators with embedded software, along with customized timing and frequency control devices for customers, worldwide. The Company was founded in 2005 and is strategically headquartered in San Jose, California with satellite offices in Middleton, Wisconsin and Hyderabad, India. Wi2Wi's manufacturing operations, its laboratory for reliability and quality control, together with design and engineering for timing and frequency control devices are located in Middleton, WI. The branch office, located in Hyderabad, India, focuses on the development of wireless connectivity; both hardware and software. Wi2Wi's strategic objective is to service the unique needs of each customer by providing end to end wireless integration solutions and highly customizable timing and frequency control devices. Wi2Wi distinguishes itself from commodity grade products, with best in the market performance, highly reliable, low power wireless connectivity products with integrated software that supports broader temperature ranges and a longer product life cycle. Furthermore, Wi2Wi's end to end product solutions helps the customer substantially reduce their end product expense, certification cost, and overall R&D investment, in addition to substantially reducing the time to market. Wi2Wi has partnered with best in class global leaders in technology, manufacturing, and sales. The Company uses a wide network of manufacturer's representatives, worldwide, to promote its products and services, and has partnered with world class distributors for the fulfillment of orders along with direct sales. Forward-Looking Statements: This news release contains certain forward-looking statements, including management's assessment of future plans and operations, and the timing thereof, that involve substantial known and unknown risks and uncertainties, certain of which are beyond the Company's control. Such risks and uncertainties include, without limitation, risks associated with the ability to access sufficient capital, the impact of general economic conditions in Canada, the United States and overseas, industry conditions, stock market volatility. The Company's actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what benefits, including the amount of proceeds, that the Company will derive there from. Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information on these and other factors that could affect the Company's operations and financial results are included in reports on file with Canadian securities regulatory authorities and may be accessed through the SEDAR website (www.sedar.com). Forward-looking statements are made based on management's beliefs, estimates and opinions on the date the statements are made and the Company undertakes no obligation to update forward-looking statements and if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law. All subsequent forward-looking statements, whether written or oral, attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Furthermore, the forward-looking statements contained in this news release are made as at the date of this news release and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. TORONTO, ON / ACCESSWIRE / February 16, 2017 / Wi2Wi Corporation (Wi2Wi or the Company) (TSX-V: YTY), announces that Mr. Daniel Phelan has resigned as a director and Chairman of the Board of Directors. Mr. Michael R. Sonnenreich and Fraser C. Henderson Sr., M.D have joined the Board of Directors and Mr. Sonnenreich was elected as the Chairman of the Board of Directors. Mr. Sonnenreich is a lawyer and a philanthropist and has extensive management experiences in various industries; Technology, Pharmaceutical and Global Marketing. He is an active stake holder and advisor to several national and international companies. Currently, Mr. Sonnenreich is the Chairman of the Board of Kikaku America International, and Vice Chairman of PharMa International Corporation of Tokyo, Japan. He is a graduate of the University of Wisconsin, the University of Madrid, Spain, and Harvard University Law School. In the past twelve years Mr. Sonnenreich has served as a board member and trustee of numerous important companies and universities, including Williams Creek Explorations, Vancouver, British Columbia, Canada; Wi2Wi, San Jose, California; Tyhee Development Corp. Ltd., Vancouver, British Columbia, Canada; Les Aliments SoYummi, Inc., Montreal, Canada; the ABD American Capital Market Funds; the Integra Fund; Continental Steel Inc.; Amorfix Life Sciences Ltd. (now Promis Neurosciences), Vancouver, British Columbia, Canada; Scientific American; and Medical Tribune International. Mr. Sonnenreich has had long-term involvement with many nonprofit institutions. These include the Washington National Opera (President 1996-98; 2002-2006); D.C. Jazz Festival (Chairman, 2010-2014); Sackler/Freer Galleries of Art (Smithsonian Institution), D.C.; Commission on the Arts and Humanities (Mayoral Appointment as Commissioner, 2008-2011); the Johns Hopkins University School of Advanced International Studies; the New England Conservatory of Music; the North Carolina Museum of Art Foundation; the University of Virginia Art Museum; Clark University; the Maret School; and the Richard Tucker Music Foundation. Mr. Sonnenreich served as President of the National Coordinating Council on Drug Education. In 2008, he was named Distinguished Washingtonian by the University Club of Washington, D.C. He previously served in government in the Department of Justice and was appointed Executive Director of the National Commission on Marijuana and Drug Abuse. Dr. Henderson is a world renowned Board-certified Neurological Surgeon and a retired US Navy Commander. He has received both his bachelor's and Medical degree from the University of Virginia, Charlottesville Virginia. He completed his fellowship in Craniospinal surgery under Professor Alan Crockard at The National Hospital for Neurology and Neurosurgery, Queen Square, London. As Part of his active duty obligations; Dr. Henderson was the Director of Spine at National Naval Medical Center, Bethesda, MD and was Brigade Neurosurgeon for the 4th Marine Expeditionary Brigade in Desert Shield and Desert Storm during the 1st Gulf War. Finishing his tour with the US Navy, Commander Henderson joined Georgetown University, in Washington D.C. as Director of Neurosurgery of the Spine and Cranio-cervical Junction. He was Co-Director of the Lombardi Neuro-Oncology Division, Co-Director of the CyberKnife Radiosurgery Center, and Medical Director of the Neuroscience Nursing Units. He was Professor of Neurosurgery and Radiology at Georgetown University, where he was active in advancing CyberKnife radiosurgery for treatment of chordoma and other complex spinal tumors. He is the Director of Neurosurgery at Doctors Hospital and Director of the Chiari Center of Excellence, where he is focused on the development of the understanding and treatment of deformity induced injury to the brainstem and spinal cord in Chiari Malformation and Ehlers Danlos Syndrome. Dr. Henderson developed intellectual property for three inventions relating to spinal radiosurgery and spinal cancer, including the TPS® -Telescopic Plate Spacer- a vertebral replacement device for metastatic disease and was Principal Investigator in the translational development of a radio-sensitizing drug, and a drug to block the malignant invasiveness of Glioblastoma Multiforme. He is an inventor of 11 devices and concepts relating to disorders of the brainstem and spinal cord, and has published over 50 peer reviewed articles and book chapters, and given over 120 invited lectures with a focus on craniocervical disorders, Chiari malformation, cancer, radiosurgery and unusual problems of the spine "We are excited to have both Mr. Sonnenreich and Mr. Henderson in the Board. Their vast experience and expertise will definitely guide the company into the successful future," said Zachariah Mathews, President and CEO of Wi2Wi. "The Board expresses its profound appreciation to Mr. Daniel Phelan for the business and financial expertise he brought to the board of directors over the past three years and helping the management of the company," said the Chairman of the Board Mr. Michael Sonnenreich. For further information, please contact: Essentially, IoT and M2M describe the network of physical objects or "things" embedded with electronics, software, sensors, and network connectivity, which enables these objects to collect and exchange data. Driven by several factors including the growth in the availability of Broadband Internet, which reduces the cost of connecting, and the related increase in Wi-Fi capabilities as well as sensors built into myriad technologies, this has been described as the "perfect storm" for the IoT. Almost any device with an on and off switch that can be connected to the Internet (and/or to each other) - anything from cell phones, coffee makers, washing machines, headphones, lamps, wearable devices, cars, as well as machine components in the engine of a jet airplane or the drill of an oil rig. According to analyst firm Gartner, by 2020 there will be over 26 billion connected devices. Others think this figure could be too conservative by a factor of four. Wi2Wi is a vertically-integrated technology company which designs, manufactures and markets high performance, low power wireless connectivity solutions, global navigation satellite system (GNSS) modules, and frequency control devices. The Company's products and services address numerous applications in the markets of Internet of Things (IoT), Machine to Machine (M2M), Avionics, Space, and Government Sponsored Projects. Wi2Wi's products and value-added services provide highly integrated, rugged, robust, and reliable multiprotocol wireless actuators with embedded software, along with customized timing and frequency control devices for customers, worldwide. The Company was founded in 2005 and is strategically headquartered in San Jose, California with satellite offices in Middleton, Wisconsin and Hyderabad, India. Wi2Wi's manufacturing operations, its laboratory for reliability and quality control, together with design and engineering for timing and frequency control devices are located in Middleton, WI. The branch office, located in Hyderabad, India, focuses on the development of wireless connectivity; both hardware and software. Wi2Wi's strategic objective is to service the unique needs of each customer by providing end to end wireless integration solutions and highly customizable timing and frequency control devices. Wi2Wi distinguishes itself from commodity grade products, with best in the market performance, highly reliable, low power wireless connectivity products with integrated software that supports broader temperature ranges and a longer product life cycle. Furthermore, Wi2Wi's end to end product solutions helps the customer substantially reduce their end product expense, certification cost, and overall R&D investment, in addition to substantially reducing the time to market. Wi2Wi has partnered with best in class global leaders in technology, manufacturing, and sales. The Company uses a wide network of manufacturer's representatives, worldwide, to promote its products and services, and has partnered with world class distributors for the fulfillment of orders along with direct sales. Forward-Looking Statements: This news release contains certain forward-looking statements, including management's assessment of future plans and operations, and the timing thereof, that involve substantial known and unknown risks and uncertainties, certain of which are beyond the Company's control. Such risks and uncertainties include, without limitation, risks associated with the ability to access sufficient capital, the impact of general economic conditions in Canada, the United States and overseas, industry conditions, stock market volatility. The Company's actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what benefits, including the amount of proceeds, that the Company will derive there from. Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information on these and other factors that could affect the Company's operations and financial results are included in reports on file with Canadian securities regulatory authorities and may be accessed through the SEDAR website (www.sedar.com). Forward-looking statements are made based on management's beliefs, estimates and opinions on the date the statements are made and the Company undertakes no obligation to update forward-looking statements and if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law. All subsequent forward-looking statements, whether written or oral, attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Furthermore, the forward-looking statements contained in this news release are made as at the date of this news release and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Loading Oncology Division collaborators
Loading Oncology Division collaborators